Foundayo (Orforglipron) for Weight Loss: 7 Facts About the New GLP-1 Pill
Foundayo(orforglipron) has moved from the clinical-trial stage into real-world U.S. obesity treatment. On April 1, 2026, the U.S. Food and Drug Administration approved Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly. It is approved for adults with obesity, or adults who are overweight and have at least one weight-related medical condition, when … Read more